SCYNEXIS, Inc. (SCYX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about SCYNEXIS, Inc. (SCYX)
Go deeper and ask any question about SCYX
Company Performance
Current Price
as of Sep 13, 2024$1.46
P/E Ratio
N/A
Market Cap
$55.27M
Description
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Metrics
Overview
- HQJersey City, NJ
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerSCYX
- Price$1.46+8.96%
Trading Information
- Market Cap$55.27M
- Float96.65%
- Average Daily Volume (1m)166,608
- Average Daily Volume (3m)141,130
- EPS-$0.85
Company
- Revenue$9.67M
- Rev Growth (1yr)-99.44%
- Net Income-$14.46M
- Gross MarginN/A
- EBITDA Margin-1,255.03%
- EBITDA-$9.24M
- EV$39.15M
- EV/Revenue4.05
- P/EN/A
- P/S7.33
Documents
SEC Filings
Factset Street Account